Zilovertamab vedotin

纬泽罗妥单抗

Report date: 2026/05/16 20:00:17

Base Information

Drug NameZilovertamab vedotin
Drug Alias NameVLS-101MK-2140
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > VC linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > MMAE payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionInactive tyrosine-protein kinase transmembrane receptor ROR1 antagonistsTubulin polymerisation inhibitors
TargetsInactive tyrosine-protein kinase transmembrane receptor ROR1Tubulin
Therapy Area/IndicationsRichter's SyndromeCarcinoma, Non-Small-Cell LungHematologic Neoplasms +[24] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[47] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesVelosbio Inc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesVelosbio IncMerck Sharp & Dohme LLCMSD R&D（China）Co Ltd
Inactive CompaniesN/A
Active IndicationsRichter's SyndromeHematologic NeoplasmsWaldenstrom Macroglobulinemia +[17] 
Inactive IndicationsCarcinoma, Non-Small-Cell LungOvarian NeoplasmsPancreatic Neoplasms +[7] 

Other Information

ATC CodeN/A
Related LinksDrugBank